AU Patent

AU2008274534B2 — Pyrimidinyl-pyridazinone derivatives

Assigned to Merck Patent GmbH · Expires 2013-05-30 · 13y expired

What this patent protects

Compounds selected from the group according to claim 1 are inhibitors of tyrosine kinases, especially of Met kinase, and can be used, inter alia, for treatment of tumours.

USPTO Abstract

Compounds selected from the group according to claim 1 are inhibitors of tyrosine kinases, especially of Met kinase, and can be used, inter alia, for treatment of tumours.

Drugs covered by this patent

tepotinib-hydrochloride (TEPOTINIB HYDROCHLORIDE)

Patent Metadata

Patent number: AU2008274534B2
Jurisdiction: AU
Classification: —
Expires: 2013-05-30
Drug substance claim: No
Drug product claim: No
Assignee: Merck Patent GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.